Receptor enzima convertidora de angiotensina y correlación con COVID-19 ¿Que conocemos hasta el momento?

Introduction: As a new disease, SARS-COV-2 is a new challenge for healthcare system worldwide, with physiopathology under study and controversy about Angiotensin Converting Enzyme Blockers use because of It’s physiopatological correlation with SARS-Cov-2. Objetive: Search for novel literature and recent recomendations about use of Angiotensin Converting Enzyme Blockers during Covid-19 illness. Materials and Methods: We look for narrative literature at PubMed Database for articules about Angiotensin Converting Enzyme and Covid-19 pandemic. Searching limit wasApril 13 of 2.020, we included all languages. Results: We included 14 articles with significative scientific contentfor review objetive.    Conclusion: SARS-Cov-2 Physiopatology is still unclear, also, pharmacology effectiveness in it’s treatment. One of these pharmacology groups are the Angiotensin Converting Enzyme Blockers with uncertainty about it’s safety during COVID-19 illness.